Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4688442 | 0.91 | ALDH1A1 (0.41) | ALDH1A1MAPK3MAPK1KCNH2MEN1 | |
| SCHEMBL3987831 | 0.89 | MEN1 (0.44) | ALDH1A1MEN1KMT2AHTTKDM4E | |
| SCHEMBL4692958 | 0.88 | MEN1 (0.47) | ALDH1A1MAPK1MEN1KMT2AHTT | |
| SCHEMBL4691908 | 0.87 | PDE3B (0.46) | ALDH1A1MEN1KMT2APDE3BPDE3A | |
| SCHEMBL14107112 | 0.86 | MAPK3 (0.43) | ALDH1A1MAPK3MAPK1KCNH2HTT | |
| SCHEMBL4688507 | 0.86 | SMN1; SMN2 (0.45) | ALDH1A1MAPK1MEN1KMT2AHTT | |
| SCHEMBL4689147 | 0.85 | KMT2A (0.53) | ALDH1A1MAPK3MAPK1MEN1KMT2A | |
| SCHEMBL4690789 | 0.84 | CRHBP (0.49) | ALDH1A1MEN1KMT2AKDM4ETSHR | |
| SCHEMBL4688350 | 0.84 | MAPK3 (0.43) | ALDH1A1MAPK3MAPK1KCNH2HTT | |
| SCHEMBL4317868 | 0.80 | MAPK3 (0.41) | MAPK3MAPK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539714-B1 | 8-HYDROXY-1-OXO-TETRAHYDROPYRROLOPYRAZINE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1539714-B1 | 8-HYDROXY-1-OXO-TETRAHYDROPYRROLOPYRAZINE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7399763-B2 | 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-7399763-B2 | 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20050288293-A1 | 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288293-A1 | 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors | TYMP, TOP1, REV1 | ALDH1A1 1715/4885MAPK3 1938/4885MAPK1 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.